Mouse LGR5/GPR49 Ready-To-Use IHC Kit

Catalog No:

RTUI0712

Product Name:

Mouse LGR5/GPR49 Ready-To-Use IHC Kit

Sample Type:

FFPE tissue

Storage:

Please store components at the temperatures indicated on the individual tube labels. The kit is stable for 6 months from the date of receipt.

Size:

50T (including a control slide)

Notes:

The positive control slide provided in the kit allows you to be sure that the experimental set-up is working properly.
Do not allow slides to dry at any time during this procedure.
Please don't replace the matching reagents in this product with other manufacturers' products.
As DAB is a carcinogen, please take necessary precautions.
PBS (reagent 1) can be stored for one week at 4℃ after preparation; The antigen retrieval buffer (1×reagent 2) and the chromogenic agent (the mixture of reagents 7 and 8) should be prepared right before each assay.

Synonyms:

FEX, GPR49, GPR67, GRP49, HG38, LGR5.

Introduction:

G protein-coupled receptor GPR49 has been reported to be expressed in brain, skeletal muscle, placenta, and spinal cord. ESTs have been isolated from normal human brain (amygdala), embryo, and placenta libraries and from human germ cell, uterus, and brain libraries. G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.